Bind therapeutics
WebJun 17, 2016 · BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND’S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ... WebJul 27, 2016 · Pfizer Inc. won bankruptcy-court approval Wednesday to buy the assets of Bind Therapeutics after an auction doubled Pfizer’s starting offer, for a final price of $40 million.
Bind therapeutics
Did you know?
WebJun 22, 2015 · BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. WebJun 22, 2015 · BIND Therapeutics is a clinical-stage nanomedicine company developing a pipeline of Accurins, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering platform to develop a pipeline …
WebNov 18, 2015 · BIND Therapeutics is a clinical-stage nanomedicine company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering® platform to develop … WebMar 7, 2024 · Oligonucleotide therapeutics brought to market thus far contain just a handful of first- and second-generation modifications, ... Interestingly, the stabilin class of scavenger receptors has been shown to bind to PS-ASOs and aid in their cellular internalization . All these tidbits aim to illustrate that making drugs out of oligonucleotides is ...
WebApr 11, 2024 · BOSTON, April 11, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., ... Preclinical data has demonstrated HST-1011's ability to bind to and inhibit a natural hotspot on CBL-B, yielding the ... WebBIND Therapeutics has raised a total of $91.8M in funding over 7 rounds. Their latest funding was raised on Feb 5, 2015 from a Post-IPO Equity round. BIND Therapeutics is registered under the ticker NASDAQ:BIND . BIND Therapeutics is funded by 6 investors. RUSNANO and NanoDimension are the most recent investors.
WebIntervention Treatment with BIND-014 at a dosage of 60 mg/m 2 was given intravenously on day 1 of 21-day cycles in combination with prednisone until disease progression or unacceptable toxic effects occurred.
WebCompany Type For Profit. Contact Email [email protected]. Phone Number (617)491-3400. They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable … small space 5-piece dining setWebMar 15, 2016 · CAMBRIDGE, Mass., March 15, 2016. — BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable … small space 110 volt clothes dryerWebMar 31, 2016 · View Full Report Card. Fawn Creek Township is located in Kansas with a population of 1,618. Fawn Creek Township is in Montgomery County. Living in Fawn … small spa water heaterWebBIND Therapeutics Inc Stock - BIND Share Price Today, News and Discussion. DIA 1.08%. SPY 1.72%. QQQ 2.27%. WAL. 8.42%. 35.43%. 5.24%. AMBI 122.94%. highway 28 laundromatWebBIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, … highway 28 albertaWebBind Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. highway 278 scWebJul 1, 2016 · BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND’S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. small space 9